Statistics for Lineage Cell Therapeutics (id:163 LCTX)
Valuation metrics
Market cap
114.62M
Enterprise value
130.15M
Trailing P/E (ttm)
-4.67
Forward P/E
-3.47
PEG ratio
-3.47
Price/Sales (ttm)
18.53
Price/Book (mrq)
1.44
Enterprise Value/Revenue
21.04
Enterprise Value/EBITDA
-6.08
Overview
Shares outstanding
220.42M
Float
146.34M
Shares short
15.94M
% Held by insiders
5.00%
% Held by institutions
3.00%
Average volume (10 days)
2.37M
Average volume (90 days)
Price summary
52-Week low
3.00
52-Week high
1.61
52-Week change
-100.00%
Beta
1.28
50-Day moving average
3.00
200-Day moving average
3.00
Dividends and splits
Forward annual dividend rate
1.25
Forward annual dividend yield
2.23
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
Ex-dividend date
January 4, 2016
Last split factor
2:1
Last split date
October 31, 1997
Financials
Fiscal yearFiscal year ends
December 31, 2023
Most recent quarter (mrq)
September 30, 2024
Profitability
Profit margin
92.50%
Operating margin
-416.69%
Operational effectiveness
Return on assets
-12.86%
Return on equity
-35.04%
Income statement
Revenue (ttm)
5.00
Revenue per share (ttm)
5.00
Quarterly revenue growth (yoy)
2.03
Gross profit (ttm)
8.27M
EBITDA
-21,397,000.00
Net income to common (ttm)
-24,187,000.00
Diluted EPS (ttm)
3.00
Quarterly earnings growth (yoy)
203.29%
Balance sheet
Total cash (mrq)
38.50M
Total cash per share (mrq)
3.00
Total debt (mrq)
2.95M
Total Debt/Equity (mrq)
4.41
Current ratio (mrq)
264.40%
Book value per share (mrq)
3.00
Cash flow
Cash flow statement
-22,015,000.00
Levered free cash flow (LFCF)
-8,912,625.00